Reported Earnings • May 16
First quarter 2026 earnings released: EPS: NT$0.17 (vs NT$0.23 in 1Q 2025) First quarter 2026 results: EPS: NT$0.17 (down from NT$0.23 in 1Q 2025). Revenue: NT$331.2m (up 4.5% from 1Q 2025). Net income: NT$38.7m (down 23% from 1Q 2025). Profit margin: 12% (down from 16% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 14
Full year 2025 earnings released: EPS: NT$0.90 (vs NT$0.48 in FY 2024) Full year 2025 results: EPS: NT$0.90 (up from NT$0.48 in FY 2024). Revenue: NT$1.40b (up 14% from FY 2024). Net income: NT$208.4m (up 94% from FY 2024). Profit margin: 15% (up from 8.8% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Duyuru • Feb 26
Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2026 Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2026. Location: 13 floor no,128, sec.6 ch`eng to rd., beitou district, taipei city Taiwan Reported Earnings • Nov 15
Third quarter 2025 earnings released: EPS: NT$0.21 (vs NT$0.023 in 3Q 2024) Third quarter 2025 results: EPS: NT$0.21 (up from NT$0.023 in 3Q 2024). Revenue: NT$316.1m (up 2.0% from 3Q 2024). Net income: NT$47.3m (up NT$42.1m from 3Q 2024). Profit margin: 15% (up from 1.7% in 3Q 2024). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to NT$28.25, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 17x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 25% over the past three years. New Risk • Sep 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (6.3% net profit margin). Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to NT$26.25, the stock trades at a trailing P/E ratio of 73.5x. Average trailing P/E is 16x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 19% over the past three years. Reported Earnings • Aug 17
Second quarter 2025 earnings released: EPS: NT$0.08 (vs NT$0.26 in 2Q 2024) Second quarter 2025 results: EPS: NT$0.08 (down from NT$0.26 in 2Q 2024). Revenue: NT$325.5m (flat on 2Q 2024). Net income: NT$18.8m (down 68% from 2Q 2024). Profit margin: 5.8% (down from 18% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 02
First quarter 2025 earnings released: EPS: NT$0.23 (vs NT$0.22 in 1Q 2024) First quarter 2025 results: EPS: NT$0.23 (up from NT$0.22 in 1Q 2024). Revenue: NT$316.9m (up 5.1% from 1Q 2024). Net income: NT$50.6m (up 4.3% from 1Q 2024). Profit margin: 16% (in line with 1Q 2024). Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to NT$36.95, the stock trades at a trailing P/E ratio of 76.8x. Average trailing P/E is 19x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 89% over the past three years. New Risk • Apr 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to NT$26.00, the stock trades at a trailing P/E ratio of 54x. Average trailing P/E is 18x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 31% over the past three years. Reported Earnings • Mar 26
Full year 2024 earnings released: EPS: NT$0.48 (vs NT$0.10 in FY 2023) Full year 2024 results: EPS: NT$0.48 (up from NT$0.10 in FY 2023). Revenue: NT$1.22b (up 37% from FY 2023). Net income: NT$107.4m (up 382% from FY 2023). Profit margin: 8.8% (up from 2.5% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Duyuru • Feb 26
Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2025 Orient Pharma Co., Ltd., Annual General Meeting, Jun 16, 2025. Location: 13 floor no,128, sec.6 ch`eng to rd., beitou district, taipei city Taiwan Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to NT$35.20, the stock trades at a trailing P/E ratio of 65.9x. Average trailing P/E is 25x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 106% over the past three years. New Risk • Nov 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to NT$31.00, the stock trades at a trailing P/E ratio of 58.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in Taiwan. Total returns to shareholders of 81% over the past three years. Buy Or Sell Opportunity • Oct 18
Now 20% overvalued Over the last 90 days, the stock has fallen 3.1% to NT$26.50. The fair value is estimated to be NT$22.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Sep 02
Now 21% overvalued Over the last 90 days, the stock has fallen 1.7% to NT$26.65. The fair value is estimated to be NT$22.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Apr 16
Full year 2023 earnings released: EPS: NT$0.10 (vs NT$0.15 loss in FY 2022) Full year 2023 results: EPS: NT$0.10 (up from NT$0.15 loss in FY 2022). Revenue: NT$889.9m (up 74% from FY 2022). Net income: NT$22.3m (up NT$51.0m from FY 2022). Profit margin: 2.5% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Duyuru • Apr 04
Orient Pharma Co., Ltd., Annual General Meeting, Jun 14, 2024 Orient Pharma Co., Ltd., Annual General Meeting, Jun 14, 2024. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$237m free cash flow). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). New Risk • Aug 17
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$237m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NT$237m free cash flow). Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding). Reported Earnings • Aug 13
First half 2023 earnings released First half 2023 results: Revenue: NT$427.2m (up 45% from 1H 2022). Net income: NT$203.0k (down 99% from 1H 2022). Profit margin: 0% (down from 6.6% in 1H 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 19
Full year 2022 earnings released: NT$0.15 loss per share (vs NT$0.55 loss in FY 2021) Full year 2022 results: NT$0.15 loss per share (improved from NT$0.55 loss in FY 2021). Revenue: NT$511.9m (up 11% from FY 2021). Net loss: NT$28.8m (loss narrowed 72% from FY 2021). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Thomas Chen was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Aug 15
First half 2022 earnings released: EPS: NT$0.10 (vs NT$0.33 loss in 1H 2021) First half 2022 results: EPS: NT$0.10 (up from NT$0.33 loss in 1H 2021). Revenue: NT$295.1m (up 62% from 1H 2021). Net income: NT$19.5m (up NT$81.3m from 1H 2021). Profit margin: 6.6% (up from net loss in 1H 2021). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Thomas Chen was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 03
Full year 2021 earnings released: NT$0.55 loss per share (vs NT$1.01 loss in FY 2020) Full year 2021 results: NT$0.55 loss per share (up from NT$1.01 loss in FY 2020). Revenue: NT$463.3m (up 13% from FY 2020). Net loss: NT$102.7m (loss narrowed 40% from FY 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Duyuru • Mar 04
Orient Pharma Co., Ltd., Annual General Meeting, Jun 30, 2022 Orient Pharma Co., Ltd., Annual General Meeting, Jun 30, 2022. Reported Earnings • Apr 17
Full year 2020 earnings released: NT$1.01 loss per share (vs NT$1.29 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: NT$412.0m (up 17% from FY 2019). Net loss: NT$171.4m (loss narrowed 15% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Duyuru • Mar 19
Orient Pharma Co., Ltd., Annual General Meeting, Jun 07, 2021 Orient Pharma Co., Ltd., Annual General Meeting, Jun 07, 2021. Is New 90 Day High Low • Jan 27
New 90-day low: NT$13.35 The company is down 14% from its price of NT$15.50 on 30 October 2020. The Taiwanese market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 16% over the same period. Reported Earnings • Jan 10
Third quarter 2020 earnings released: NT$0.13 loss per share The company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: NT$116.3m (up 26% from 3Q 2019). Net loss: NT$23.6m (loss narrowed 38% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 07
New 90-day low: NT$14.30 The company is down 16% from its price of NT$17.05 on 08 October 2020. The Taiwanese market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 15% over the same period. Is New 90 Day High Low • Dec 08
New 90-day low: NT$14.45 The company is down 20% from its price of NT$18.00 on 09 September 2020. The Taiwanese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 11% over the same period. Is New 90 Day High Low • Nov 02
New 90-day low: NT$15.15 The company is down 27% from its price of NT$20.80 on 04 August 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Sep 25
New 90-day low: NT$15.50 The company is down 32% from its price of NT$22.75 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 4.0% over the same period.